This was the stock's third consecutive day of losses.

AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic ...

Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...